Does Rallies show 13F holders for ZBIO?

Yes. Rallies tracks hedge fund and 13F ownership data for ZBIO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ZBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ZBIO. It does not provide personalized investment advice.

ZBIO (Zenas BioPharma, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Zenas BioPharma, Inc. Common Stock (ZBIO) is a publicly traded Healthcare sector company. As of May 19, 2026, ZBIO trades at $17.71 with a market cap of $1.16B and a P/E ratio of -1.38. ZBIO moved -7.96% today. Year to date, ZBIO is -50.99%; over the trailing twelve months it is +61.51%. Its 52-week range spans $5.83 to $44.60. Analyst consensus is strong buy with an average price target of $43.67. Rallies surfaces ZBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ZBIO stock?

Hedge funds tracked by Rallies that own ZBIO include Soros Fund. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Zenas BioPharma, Inc. Common Stock.

ZBIO Key Metrics

Key financial metrics for ZBIO
Metric	Value
Price	$17.71
Market Cap	$1.16B
P/E Ratio	-1.38
EPS	$-11.89
Dividend Yield	0.00%
52-Week High	$44.60
52-Week Low	$5.83
Volume	1.13K
Avg Volume	0
Revenue (TTM)	$5.00M
Net Income	$-156.99M
Gross Margin	0.00%

Top Hedge Funds Holding ZBIO

Soros Fund holds 37.50K shares of ZBIO, changed +0.00% as of Sep 30, 2024.

Latest ZBIO News

Zenas BioPharma Grants 51,075 RSUs to New Hires, Vesting 2027–2030 — May 18, 2026
Zenas BioPharma Doses First Subject in Phase 1 Trial of Oral IL-17AA/AF Inhibitor — May 13, 2026
Zenas BioPharma Eyes FDA BLA After 56% IgG4-RD Flare Reduction, Cash to 2029 — May 13, 2026
Zenas BioPharma Secures $287.5M Net from $200M Convertible Notes and $100M Equity Offering — Mar 27, 2026
Zenas BioPharma Proposes 2032 Convertible Notes and Common Stock Offerings with 15% Option — Mar 26, 2026

Recent ZBIO Insider Trades

MOULDER LEON O JR bought 60.00K (~$1.01M) on May 18, 2026.
MOULDER LEON O JR bought 35.00K (~$616.70K) on Apr 29, 2026.
MOULDER LEON O JR bought 25.00K (~$450.50K) on Apr 28, 2026.

ZBIO Analyst Consensus

6 analysts cover ZBIO: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $43.67.

Common questions about ZBIO

Who owns ZBIO stock?: Hedge funds tracked by Rallies that own ZBIO include Soros Fund. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Zenas BioPharma, Inc. Common Stock.
Does Rallies show 13F holders for ZBIO?: Yes. Rallies tracks hedge fund and 13F ownership data for ZBIO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ZBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ZBIO. It does not provide personalized investment advice.